Gene therapy: a 2001 perspective

Area of Science:

• Hematology
• Gene Therapy
• Translational Medicine

Background:

• Gene therapy research for hemophilia has progressed significantly.
• Three clinical trials for hemophilia gene therapy have recently begun.
• Preclinical studies have laid the groundwork for clinical translation.

Purpose of the Study:

• To review the fundamental principles of gene therapy for hemophilia.
• To provide an overview of the current clinical trials in hemophilia gene therapy.
• To discuss the potential of adeno-associated virus (AAV) vectors in treating hemophilia.

Main Methods:

• Review of basic gene therapy concepts for hemophilia.
• Outline of current clinical trial designs, focusing on dose escalation.
• Description of an ongoing hemophilia B trial using intramuscular AAV vector delivery of human factor IX.

Main Results:

• Preclinical studies demonstrated therapeutic levels of factor IX in animal models.
• The ongoing trial utilizes a dose escalation design.
• Adeno-associated virus (AAV) vectors are being investigated for factor IX expression.

Conclusions:

• It is premature to determine the efficacy of current gene therapy strategies for hemophilia.
• Early clinical trials are exploring AAV-mediated gene therapy for hemophilia B.
• Preclinical success in animal models supports the advancement of these AAV-based strategies.